<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75537">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01895244</url>
  </required_header>
  <id_info>
    <org_study_id>AST MOMA</org_study_id>
    <nct_id>NCT01895244</nct_id>
  </id_info>
  <brief_title>Highdose Chemotherapy and Transplantation of 34+ Selected Stem Cell for Progressive Systemic Sclerosis - Modification According to Manifestation</brief_title>
  <acronym>AST MOMA</acronym>
  <official_title>Highdose Chemotherapy and Transplantation of 34+ Selected Stem Cell for Progressive Systemic Sclerosis - Modification According to Manifestation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autologous stem cell therapy has been shown to be effective in patients with systemic
      sclerosis. Nevertheless treatment is associated with treatment related mortality and
      patients die during follow up despite successful transplantation.

      Intention of this trial is to improve overall survival by modifying the existing protocol
      used for the ASTIS trial.

      To reduce treatment toxicity we reduce the dose of Cyclophosphamide (CYC) for mobilisation
      to 2x1g.

      Especially in patients with cardiac manifestations we also modify the conditioning regimen
      by adding thiotepa and reducing CYC; as CYC has known cardiotoxic side effects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment related mortality</measure>
    <time_frame>100 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Treatment related mortality: number of patients who die during the first 100 days after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to engraftment</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Time in days from day 0 to platelet count &gt; 20.000 and granulocytes &gt;500/µl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time after transplantation without symptoms of disease activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reduction of modified Rodnan Skin score (mRSS) after transplantation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient reported outcome</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Differences in Health Assessment Questionnaire (HAQ)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Scleroderma</condition>
  <condition>Cardiac Involvement</condition>
  <condition>Autologous Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Conditioning with CYC/ antithymocyte globulin (ATG)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient receives stem cell transplantation open label with cluster of differentiation (CD)34 selected stem cells mobilisation and conditioning depending on manifestation If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conditioning with CYC/Thiotepa/ATG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In patients with cardiac manifestations as defined in the protocol the conditioning for stem cell transplantation is changed to Cyclophosphamide (CYC), thiotepa and ATG</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells</intervention_name>
    <description>If no active alveolitis: mobilisation with 2x1g Cyclophosphamide If active alveolitis: mobilisation with 2x1.5g Cyclophosphamid If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG</description>
    <arm_group_label>Conditioning with CYC/ antithymocyte globulin (ATG)</arm_group_label>
    <arm_group_label>Conditioning with CYC/Thiotepa/ATG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of progressive systemic sclerosis &lt;7 years

          -  Progressive course despite cyclophosphamide pretreatment

          -  Cyclophosphamide i.v.: at least 3 x with 500-1000 mg/m² every 3-4 weeks or

          -  Cyclophosphamide p.o. with at least 100mg/day for at least 2 months or

          -  Contraindication to treatment with cyclophosphamide

          -  Progress defined as at least one of the following criteria:

               -  Increase in the mRSS

               -  Worsening of the lung function

               -  Increase in fibrosis/alveolitis in thorax CT

               -  Worsening kidney function through manifestation of systemic sclerosis

          -  Limited or diffuse cutaneous progressive form of Ssc with organ manifestation in the
             lungs/heart or kidneys

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Pregnancy or inadequate contraception

          -  Severe heart failure with ejection fraction (EF) &lt; 30% in echo

          -  Pulmonary arterial hypertension with systolic pulmonary arterial pressure (PAPsys)
             &gt;50mm Hg

          -  Kidney insufficiency: creatinine clearance &lt;30 ml/min

          -  Reduced lung function

          -  Inspiratory vital capacity (IVC) &lt; 50% of normal

          -  Carbon monoxide (CO)-Diffusion capacity &lt; 30%

          -  Previously damaged bone marrow

          -  Leukopenia &lt; 2,000/µl

          -  Thrombopenia &lt; 100,000/µl

          -  Previous myelotoxic treatment:

          -  Cyclophosphamide &gt; 50g cumulative (relative)

          -  Infection (Hepatitis B/C, HIV, Salmonella carrier, syphilis, relative: history of
             tuberculosis)

          -  Severe concomitant  psychiatric illness (depression, psychosis)

          -  Substance dependence

          -  Continued nicotine abuse

          -  Continued alcohol abuse

          -  Continued drug abuse

          -  Consent not given

          -  Poor compliance
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joerg C Henes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tuebingen, Department of oncology, hematology, rheumatology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joerg C Henes, MD</last_name>
    <phone>+4970712982711</phone>
    <email>joerg.henes@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Theodoros Xenitidis, MD</last_name>
    <phone>+4970712982711</phone>
    <email>theodoros.xenitidis@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Tuebingen; Department of oncology, hematology, rheumatology, immunology and pulmology</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joerg C Henes, MD</last_name>
      <phone>+4970712982711</phone>
      <email>joerg.henes@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Theodoros Xenitidis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Moehle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 11, 2013</lastchanged_date>
  <firstreceived_date>July 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Joerg Henes</investigator_full_name>
    <investigator_title>Dr. med. Joerg Henes</investigator_title>
  </responsible_party>
  <keyword>scleroderma</keyword>
  <keyword>autologous stem cell transplantation</keyword>
  <keyword>thiotepa</keyword>
  <keyword>cluster of differentiation (CD) 34 selection</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
